These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Investigation of the criteria for assessing the outcome of treatment in acromegaly. Lindholm J; Giwercman B; Giwercman A; Astrup J; Bjerre P; Skakkebaek NE Clin Endocrinol (Oxf); 1987 Nov; 27(5):553-62. PubMed ID: 3450453 [TBL] [Abstract][Full Text] [Related]
24. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Diamond T; Nery L; Posen S Ann Intern Med; 1989 Oct; 111(7):567-73. PubMed ID: 2774387 [TBL] [Abstract][Full Text] [Related]
25. Supranormal stimulation of deoxyribonucleic acid synthesis in FRTL5 cells by serum from patients with untreated acromegaly. Misaki T; Maciel RM; Tramontano D; Moses AC; Lombardi A; Ingbar SH J Clin Endocrinol Metab; 1988 Jun; 66(6):1227-32. PubMed ID: 3372685 [TBL] [Abstract][Full Text] [Related]
26. Somatomedin-C in active and successfully treated acromegaly. Knappe G; Hesse V; Jahreis G; Rohde W; Gerl H Exp Clin Endocrinol; 1988 Mar; 91(1):2-6. PubMed ID: 3371416 [TBL] [Abstract][Full Text] [Related]
27. Discrepancies between bioassayable somatomedin activity and somatomedin C levels in acromegalic patients. Jasper HG; Artese R; Molocznik I; Bruno O Medicina (B Aires); 1986; 46(4):440-4. PubMed ID: 3574106 [No Abstract] [Full Text] [Related]
28. Disappearance rate of endogenous and exogenous human growth hormone in man. Refetoff S; Sönksen PH J Clin Endocrinol Metab; 1970 Mar; 30(3):386-92. PubMed ID: 5412545 [No Abstract] [Full Text] [Related]
29. Abnormalities of growth hormone release in response to human pancreatic growth hormone releasing factor (GRF (1-44) ) in acromegaly and hypopituitarism. Wood SM; Ch'ng JL; Adams EF; Webster JD; Joplin GF; Mashiter K; Bloom SR Br Med J (Clin Res Ed); 1983 May; 286(6379):1687-91. PubMed ID: 6405935 [TBL] [Abstract][Full Text] [Related]
30. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. Lamberts SW; Uitterlinden P; del Pozo E J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785 [TBL] [Abstract][Full Text] [Related]
31. Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. Páramo C; Fluiters E; de la Fuente J; Andrade A; García-Mayor RV Metabolism; 2001 Sep; 50(9):1117-21. PubMed ID: 11555849 [TBL] [Abstract][Full Text] [Related]
32. Bioassayable growth hormone activity in blood from healthy individuals and acromegalic patients. Thorngren KG; Hallengren B Acta Endocrinol (Copenh); 1986 Jan; 111(1):3-9. PubMed ID: 3946103 [TBL] [Abstract][Full Text] [Related]
33. The measurement of insulin-like growth factor I: clinical applications and significance. Teale JD; Marks V Ann Clin Biochem; 1986 Jul; 23 ( Pt 4)():413-24. PubMed ID: 3094423 [TBL] [Abstract][Full Text] [Related]
34. [Effect of L-arginine perfusion on plasma levels of S.T.H. in the normal and pathologic patient]. Argemi B; Jaquet P; Martin-Laval C; Oliver C; Vague P; Pierron H; Vague J Mars Med; 1972; 109(1):1-9. PubMed ID: 4623008 [No Abstract] [Full Text] [Related]